A case of takotsubo cardiomyopathy precipitated by lumiracoxib, a selective COX-2 inhibitor.
Considerable controversy exists regarding the cardiovascular safety of COX-2 inhibitors, both in patients with and without established cardiovascular disease. Currently, the major focus is on thrombotic complications presenting as myocardial infarction. I n this report, we present a case of takotsubo cardiomyopathy, also known as the apical ballooning syndrome, precipitated by the use of lumiracoxib. We are concerned that this might be the first case of COX-2 inhibitor-induced apical ballooning syndrome and that more may follow.
Ker
J
J
Department of Physiology, University of Pretoria and Pretoria Heart Hospital, Pretoria.
Van Wyk
C J
CJ
D000368:Aged; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004008:Diclofenac / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D054549:Takotsubo Cardiomyopathy / Q000139:chemically induced*
D052246:Cyclooxygenase 2 Inhibitors; D004008:Diclofenac; C473384:lumiracoxib